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Brief Definitive Report
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Innate immune receptors for pathogen- and damage-associated molecular patterns (PAMPs
and DAMPs) orchestrate inflammatory responses to infection and injury. Secreted by activated immune cells or passively released by damaged cells, HMGB1 is subjected to redox
modification that distinctly influences its extracellular functions. Previously, it was unknown how the TLR4 signalosome distinguished between HMGB1 isoforms. Here we demonstrate that the extracellular TLR4 adaptor, myeloid differentiation factor 2 (MD-2), binds
specifically to the cytokine-inducing disulfide isoform of HMGB1, to the exclusion of other
isoforms. Using MD-2–deficient mice, as well as MD-2 silencing in macrophages, we show
a requirement for HMGB1-dependent TLR4 signaling. By screening HMGB1 peptide libraries, we identified a tetramer (FSSE, designated P5779) as a specific MD-2 antagonist
preventing MD-2–HMGB1 interaction and TLR4 signaling. P5779 does not interfere with
lipopolysaccharide-induced cytokine/chemokine production, thus preserving PAMP-mediated
TLR4–MD-2 responses. Furthermore, P5779 can protect mice against hepatic ischemia/
reperfusion injury, chemical toxicity, and sepsis. These findings reveal a novel mechanism by
which innate systems selectively recognize specific HMGB1 isoforms. The results may direct
toward strategies aimed at attenuating DAMP-mediated inflammation while preserving
antimicrobial immune responsiveness.

After infection or injury, the immediate host
inflammatory response is mediated by receptors
on innate immune cells that can efficiently recognize pathogen- or damage-associated molecular
patterns (PAMPs or DAMPs). For instance, the
mammalian response to bacterial endotoxin (LPS)
is mediated by the LPS-binding protein (LBP),
CD14, MD-2, and TLR4. Upon capturing LPS,
LBP transfers it to CD14 and MD-2, which
then delivers LPS to the signaling, high-affinity
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this paper.
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transmembrane receptor TLR4 (Nagai et al.,
2002).The engagement of LPS with TLR4 triggers the sequential release of “early” (e.g., TNF,
IL-1, and IFN-) and “late” proinflammatory
mediators (e.g., HMGB1; Wang et al., 1999).
As a ubiquitous nuclear protein, HMGB1 can
be passively released from damaged cells (Scaffidi
et al., 2002) after sterile tissue injury as a result
© 2015 Yang et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.rupress.org/terms). After six months
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/
licenses/by-nc-sa/3.0/).



Figure 1. Disulfide HMGB1 binds to MD-2. (A) TNF release was measured from RAW 264.7 cells stimulated with various isoforms of HMGB1 as
indicated (1 µg/ml, 16 h). Data are presented as means ± SEM. *, P < 0.05 versus disulfide HMGB1. n = 3–5 experiments. (B) SPR (Biacore) analysis was
performed to assess HMGB1 binding to MD-2 or TLR4 (coated on the chip). (top) HMGB1 binding to human MD-2 was tested at different HMGB1 concentrations (12.5, 25, 50, and 100 nM) with an apparent Kd of 12 nM (left). Human MD-2 (12.5, 25, 50, and 100 nM) binding to HMGB1 (coated on the
chip; middle) and disulfide HMGB1 (100 nM) binding to TLR4 (coated on the chip; right) were tested. (bottom) Noncytokine-inducing HMGB1 (C106A,
Hg-HMGB1, 1 µM) was tested for binding to MD-2 (coated on the chip; left). HMGB1 isoforms were tested for binding to MD-2 (coated on the chip;
right). Data are presented as response units or relative response units over time (seconds) and are representative of three experiments. (C) Mixture of
CBP-tagged HMGB1 or CBP alone with supernatant of yeast Sf9 cells expressing MD-2 was immunoprecipitated with calmodulin beads (immunoprecipitation [IP]), and immunoblotted (IB) with anti–human MD-2 or CBP antibodies. Recombinant MD-2 protein was included as positive control (right lane).
Data shown are representative of three repeats. (D) SPR analysis of HMGB1 binding to human MD-2 (coated on the chip) was performed in the presence
of anti-HMGB1 mAb (left) or irrelevant mouse IgG (right) as shown. Data are representative of three repeats.

of ischemia/reperfusion (I/R; Tsung et al., 2005) or chemical
toxicity (Antoine et al., 2013). HMGB1 can signal through a
family of receptors, including RAGE (Huttunen et al., 1999),
TLR4 (Yang et al., 2010), and cluster of differentiation 24
(CD24)/Siglec-10 (Chen et al., 2009), thereby functioning as
a DAMP that alerts, recruits, and activates innate immune
cells to produce a wide range of cytokines and chemokines.
Thus, seemingly unrelated conditions such as infection and
sterile injury can converge on a common process: inflammation, which is orchestrated by HMGB1 actively secreted from
innate immune cells or passively released from damaged tissues (Zhang et al., 2010; Andersson and Tracey, 2011). Extracellular HMGB1 has been established as a pathogenic mediator
of both infection- and injury-elicited inflammatory diseases
(Yang et al., 2013).
HMGB1 is a redox-sensitive protein as it contains three
conserved cysteine residues at position 23, 45, and 106. The
redox status of the cysteines dictates its extracellular chemokineor cytokine-inducing properties. Specifically, HMGB1 with
all cysteine residues reduced (fully reduced HMGB1) binds
to CXCL12 and stimulates immune cell infiltration via the
CXCR4 receptor in a synergistic fashion. Partially oxidized
HMGB1, with a Cys23-Cys45 disulfide bond and a reduced


Cys106 (disulfide HMGB1), activates immune cells to produce
cytokines/chemokines via the TLR4 receptor. Once all cysteines are terminally oxidized (sulfonyl HMGB1), HMGB1 is
devoid of chemotactic and cytokine activities (Tang et al., 2012;
Venereau et al., 2012). Previously we showed that HMGB1
induces inflammatory responses via the TLR4–MD-2 signaling pathway and that the interaction with TLR4–MD-2 requires a specific HMGB1 redox form with a distinct atomic
structure of thiol-cysteine 106 (Yang et al., 2012). Ample evidence suggests that HMGB1, when actively secreted by activated immune cells or passively released from dying cells, is a
mixture of several isoforms with distinct posttranslational
modifications (Yang et al., 2013). Paradoxically, it is unknown
how the immune system uses the TLR4–MD-2 receptor
system to distinguish between different isoforms of HMGB1,
specifically recognizing the disulfide HMGB1 molecule to
the exclusion of other isoforms.
MD-2 carries a hydrophobic pocket folded by two antiparallel -sheets for binding LPS (Park et al., 2009) and confers
molecular specificity for LPS interaction and TLR4 signaling
(Nagai et al., 2002; Meng et al., 2010). Accordingly, here we
reasoned that MD-2 may similarly discriminate different
HMGB1 isoforms to facilitate TLR4-dependent signaling.
MD-2–HMGB1 interplay and TLR4 signaling | Yang et al.
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Figure 2. MD-2 is indispensable for HMGB1-dependent TLR4 signaling. (A, top) Knockdown of MD-2 (siRNA) was performed on RAW 264.7
cells. MD-2 and NF-B levels (p65) were assessed by Western blotting. The level of NF-B (p65) protein was normalized relative to the level of
-actin (ratio) by densitometry and expressed as the fold change over unstimulated cells. (bottom) HMGB1-induced TNF release from RAW 264.7
cells with MD-2 knockdown (open bars) or control siRNA (closed bars). *, P < 0.05 versus control siRNA group. n = 4–5 experiments. (B, left) HMGB1
(2 µg/ml) or ultrapure LPS (200 ng/ml) was used to stimulate primary peritoneal macrophages from WT or MD-2 KO mice for 16 h, and NF-B
(p50 and p65) protein levels in nuclear extracts were assessed by Western blotting (top left). NF-B activation is expressed as of p50 or p65 relative
to -actin and calculated as the fold change over unstimulated cells (bottom left). (right) Mouse macrophages were stimulated with HMGB1 and
cytokine release was measured using mouse cytokine antibody array (G-CSF, IL-12p40, IL-6, TNF, RANTES, MCP-1, and sTNFR1; top right) or ELISA
(for TNF; bottom right). *, P < 0.05 versus WT group. n = 5 separate experiments. (C, left) WT or MD-2 KO mice were challenged with APAP in a liver
injury model and were euthanized 24 h later to measure serum levels of liver enzymes (GLDH, ALT, and AST; left column of graphs) and cytokines
(HMGB1, TNF, and IL-6; right column of graphs). *, P < 0.05 versus WT APAP group. n = 5–13 mice per group. (middle) Representative H&E staining
of liver tissues from these mice are shown. n = 5–8 mice per group (the arrow indicates necrosis region). Bars, 100 µm. (right) Animal survival after
receiving a lethal dose of APAP in WT and MD-2 KO mice was assessed (percent survival). *, P < 0.05 versus WT. n = 15 mice per group. (A–C) Data
are presented as means ± SEM.

Our current findings reveal that only the disulfide HMGB1
binds to MD-2, and this interaction is critically important for
HMGB1-mediated cytokine/chemokine production and the
development of subsequent tissue injury. Screening of HMGB1
peptide libraries identified a tetramer (FSSE, P5779) as a specific MD-2–targeting antagonist that prevents HMGB1–MD-2
interaction and cytokine induction, thereby protecting animals against liver I/R injury, chemical toxemia, and sepsis.
JEM Vol. 212, No. 1

RESULTS AND DISCUSSION
Cytokine-inducing (disulfide) HMGB1
effectively binds to MD-2
HMGB1 contains three redox-sensitive cysteine residues that
are modified by redox reactions to produce multiple HMGB1
isoforms that extracellularly express or lack chemokine or cytokine activities. To elucidate the underlying molecular mechanisms, we examined whether MD-2, an extracellular adaptor


thiol-cysteine 106 in the regulation of HMGB1 cytokine activity (Fig. 1, A and B).
To further study HMGB1–MD-2 interactions, immunoprecipitation assays were used to pull down MD-2 from HMGB1expressing cell lysates. Co-incubation with calmodulin-binding
protein (CBP)–tagged disulfide HMGB1, but not CBP tag
alone, pulled down MD-2 protein from yeast cells transfected
with an MD-2–expressing construct (Fig. 1 C), confirming
that MD-2 binds disulfide HMGB1. Furthermore, this interaction was blocked by anti-HMGB1 mAbs, but not by irrelevant IgG, demonstrating that the HMGB1–MD-2 interaction
is specific and targetable by antagonists (Fig. 1 D).

Figure 3. Anti-HMGB1 mAb administration ameliorates APAPinduced liver injury in mice. (A) Mice received an APAP injection (i.p.)
followed by treatment with an anti-HMGB1 antibody or control IgG injection (i.p.; see Materials and methods). Animal survival (percent survival)
was assessed. n = 20 mice/group. *, P < 0.05 versus IgG group. (B) Serum
levels of liver enzyme (ALT) and cytokines (TNF and IL-6) at 24 h after
APAP were measured in mice receiving treatment of anti-HMGB1 antibody or control IgG (see Materials and methods). *, P < 0.05 versus IgG
group. n = 10 mice/group. (A and B) Data are presented as means ± SEM.

receptor of the TLR4 signalosome, can discriminate various
HMGB1 isoforms with their distinct inflammatory properties.
Different forms of HMGB1, produced by point mutations or
chemical modifications by exposure to mercury thiolates or
the reducing agent dithiothreitol, were tested for their MD-2–
binding properties. Consistent with previous studies (Venereau
et al., 2012;Yang et al., 2012), only the disulfide HMGB1 isoform induced TNF secretion (Fig. 1 A). Biosensor-based surface plasmon resonance (SPR) analysis (Biacore) confirmed
that only the disulfide HMGB1 binds to MD-2 with high affinity (apparent Kd = 12 nM) regardless of whether MD-2 or
HMGB1 was immobilized on the sensor chip (Fig. 1 B). In
contrast, HMGB1 was incapable of directly binding to TLR4
(Fig. 1 B) in the absence of MD-2, although TLR4 was functionally active in MD-2 binding in Biacore analysis (not depicted), implicating MD-2 as an essential participant in the
HMGB1–TLR4 signaling pathway. Unlike the disulfide isoform of HMGB1, H2S modified, fully reduced, or sulfonyl
HMGB1 failed to induce TNF release from macrophage
cultures (Fig. 1 A), with >1,000-fold reduction in MD-2
binding as compared with disulfide HMGB1 (Fig. 1 B).
Notably, chemical modification of the cysteine 106 of the
disulfide HMGB1 also abolished the TNF-stimulating and
MD-2–binding properties, indicating a critical role of the


MD-2 is required for HMGB1-mediated
inflammatory responses
To further assess the importance of MD-2 in HMGB1-mediated
cytokine induction, we used siRNA to knock down MD-2
expression in murine macrophage-like RAW 264.7 cells or
human (THP-1) monocytes. The silencing of MD-2 expression (by 80–90%) was accompanied by a significant reduction
of HMGB1-stimulated NF-B activation and TNF release in
both murine macrophages and human monocytes (Fig. 2 A
and not depicted). To confirm the requirement for MD-2 in
HMGB1-induced innate immune activation, thioglycollateelicited peritoneal macrophages were isolated from WT and
MD-2 KO mice and stimulated by disulfide HMGB1. Disruption of MD-2 expression resulted in complete impairment of both LPS- and HMGB1-induced activation of NFB and secretion of cytokines (TNF and IL-6) and chemokines
(e.g., RANTES and MCP-1; Fig. 2 B).The release of IL-12/p40
stimulated with HMGB1 is via an MD-2–independent mechanism, likely attributable to signaling via other receptors.
HMGB1 is an important mediator of acetaminophen
(APAP)-induced hepatotoxicity (Antoine et al., 2012).To evaluate the in vivo importance of MD-2 in HMGB1-induced
inflammatory responses, we studied the impact of MD-2 deficiency on sterile inflammation using the APAP intoxication
model.The disruption of MD-2 expression resulted in a significant reduction in acute hepatic injury, as assessed by liver
enzyme release (glutamate dehydrogenase [GLDH], aspartate
aminotransferase [AST], and alanine aminotransferase [ALT])
and histological analysis of liver necrotic lesions compared with
WT mice subjected to APAP injection (Fig. 2 C, arrow). Furthermore, the lessened hepatic damage in MD-2 KO mice was
accompanied by significant reduction in cytokine (TNF and
IL-6) release and APAP-induced animal lethality, confirming
an essential role for MD-2 in sterile inflammation and injury
(Fig. 2 C). Notably, serum HMGB1 levels were comparably
elevated in WT and MD-2 KO mice at 24 h after APAP administration (Fig. 2 C).The central role of HMGB1 in APAP-induced
liver toxicity was further confirmed by using an HMGB1neutralizing mAb, which significantly inhibited APAPinduced release of hepatic enzymes (ALT) and proinflammatory
cytokines (TNF and IL-6) and improved survival (Fig. 3).
Collectively, these in vivo experimental data reveal an essential
role for MD-2 and HMGB1 in the pathogenesis of sterile injury.
MD-2–HMGB1 interplay and TLR4 signaling | Yang et al.
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Figure 4. Screening for HMGB1 inhibitors. (A) SPR analysis was performed to test the interaction of MD-2 (coated on
the chip) with P5779 (FSSE) and other peptides (100 nM).
Kd values are shown. Data are representative of three experiments. (B) Primary human macrophages were stimulated
in vitro with HMGB1 (1 µg/ml) plus different peptides (50 µg/ml)
for 16 h, and TNF release was measured by ELISA. Data are presented as means ± SEM. *, P < 0.05 versus HMGB1 alone. n = 4–5
experiments. (C) SPR analysis was performed to measure binding of P5779 (12.5, 25, 50, and 100 nM) or scrambled control
(ctrl) peptide (100 nM) to human MD-2 (Kd = 0.65 µM for
P5779), HMGB1, or TLR4 (coated on the chip). Data are representative of three experiments. (D) Schematic illustration
showing molecular docking of MD-2 with tetramer peptides
FSSE (left) and SFSE (right). The pink area represents the surface of the peptide-binding pocket of MD-2, and the green
area denotes the TLR4 protein surface. The bottom panel shows
hydrogen bonds and van der Waals interactions. P5779, with
a stronger van der Waals interaction than control, is fully extended into the hydrophobic pocket of MD-2 and forms an
additional hydrogen bond with Tyr102 of MD-2.

Development of a novel MD-2–binding peptide
as an HMGB1-specific inhibitor
Having identified a critical involvement of the cysteine 106 region of HMGB1 in HMGB1–MD-2 interaction and HMGB1–
TLR4 signaling, we used a rational strategy to screen for
mimetic peptide inhibitors. A series of trimer and tetramer
peptides spanning the cysteine 106 region and incorporating
cysteine homologues were screened for MD-2–binding properties using the Biacore technology and molecular docking
technique (Fig. 4,A, C, and D). Although most peptides lacked
MD-2–binding capacity, we identified one epitope within
the HMGB1 B box domain that acted as a potent HMGB1specific inhibitor. Molecular docking simulation revealed
that the FSSE (P5779) tetramer fully extended into the hydrophobic pocket of MD-2, thereby forming maximal van der
Waals interaction with surrounding hydrophobic residues
along with an additional hydrogen bond with the Tyr102
(Fig. 4 D). Consequently, it bound to MD-2 with a Kd value
of 0.65 µM and significantly inhibited HMGB1-induced
TNF release from human macrophages (Fig. 4, A and B). This
interaction was specific, as P5779 failed to bind to other proteins such as HMGB1 and TLR4 in the absence of MD-2
(Fig. 4 C). Similarly, scrambling the amino acid sequence of
P5779 (control peptide) abolished the MD-2–binding capacity in Biacore experiments (Fig. 4 C) and in molecular docking analysis (Fig. 4 D).
JEM Vol. 212, No. 1

To evaluate the therapeutic potential of the MD-2–binding
peptide, we next studied whether P5779 was capable of
disrupting MD-2–HMGB1 interactions, thereby inhibiting
HMGB1-induced cytokine production. P5779 inhibited the
MD-2–HMGB1 interaction in a concentration-dependent
manner when either MD-2 or HMGB1 was coated onto the
Biacore sensor chip (Fig. 5 A). Furthermore, P5779 inhibited
HMGB1-induced TNF release in primary human macrophages in a concentration-dependent fashion (Fig. 5 B). The
effective concentration of P5779 that suppressed 50% TNF
release (IC50) was 5 µg/ml in the presence of HMGB1 at
1 µg/ml. Scrambling the amino acid sequence of P5779 abolished the capacity to inhibit HMGB1-induced TNF release
(Fig. 5 B). Exposure of macrophages to P5779 failed to inhibit
TNF release mediated by polyinosinic-polycytidylic acid
(Poly I:C), S100A12, LPS, peptidoglycan (PGN), and CpG
DNA (Fig. 5 B). P5779 also significantly reduced HMGB1induced release of other cytokines including IL-6 and IL12p40/p70 and chemokines such as RANTES and MCP-1
(Fig. 5 C). P5779 did not inhibit LPS-stimulated cytokine/
chemokine release in vitro in macrophages (Fig. 5 D) and
failed to attenuate LPS-induced systemic cytokine levels
in vivo, even when administered at high doses (8 mg/kg) in
mice (Fig. 5 E). Thus, P5779 selectively attenuates HMGB1–
MD-2–TLR4 signaling without inhibiting macrophage activation in response to PAMPs.


Figure 5. Development of a tetramer peptide (P5779) as an MD-2–binding HMGB1-specific inhibitor. (A) On SPR analysis, HMGB1 was coated
on the chip and MD-2 (1 µM) was flowed over as analyte, plus different amounts of P5779 as shown. Inhibition of HMGB1 binding to MD-2 by P5779
(IC50 = 29 nM) was assessed (top). In the reverse experiment, human MD-2 was coated on the chip, and HMGB1 (1 µM) plus different amounts of P5779
were added as analytes. HMGB1 binding to MD-2 was inhibited by P5779 (IC50 = 2 nM; bottom). Data are representative of three separate experiments.
(B) Human primary macrophages, isolated from human blood, were stimulated with HMGB1 (1 µg/ml) or other stimuli (Poly I:C, S100A12, LPS, PGN, and
CpG DNA) in vitro, plus increasing amounts of P5779 (or scrambled control peptide) for 16 h. TNF release was measured by ELISA. *, P < 0.05 versus
HMGB1 plus control peptide (ctrl). n = 4–5 experiments. (C) Thioglycollate-elicited peritoneal mouse macrophages were stimulated in vitro with HMGB1
(1 µg/ml) plus P5779 or control peptide (50 µg/ml) for 16 h, and extracellular levels of various cytokines were analyzed by mouse cytokine antibody array
(left). Data are representative of three to four experiments, each performed in duplicate and expressed as fold increase over unstimulated cells using densitometry (-HMGB1; right table). *, P < 0.05 versus +HMGB1 group. (D) Primary human macrophages, isolated from blood, were stimulated in vitro with
LPS (2 ng/ml) for 16 h in the absence or presence of P5779 (50 µg/ml) or control peptide, and extracellular levels of various cytokines were analyzed by
human cytokine antibody array. Data are representative of three repeats. (E) Male C57BL/6 mice received an LPS injection (8 mg/kg, i.p.) plus P5779 or
control peptide (500 µg/mouse, i.p.). Animals were euthanized 90 min later. Serum TNF and IL-6 levels were measured by ELISAs. n = 5 mice per group.
(B and E) Data are presented as means ± SEM.

Therapeutic efficacy of MD-2–targeted P5779
in APAP toxicity, ischemia, and sepsis
In the APAP-induced liver toxicity model, P5779 treatment
dose-dependently reduced APAP-induced elevation of hepatic serum enzymes (AST and ALT), proinflammatory cytokines (TNF), liver necrosis, and improved survival (Fig. 6 A,
arrow). In sterile injury mediated by hepatic I/R, P5779 also
significantly blunted hepatic serum enzyme release (AST and
ALT) and neutrophil infiltration (Fig. 6 B, arrow). In addition,
treatment with P5779 in a sepsis model induced by cecal ligation and puncture (CLP) significantly and dose-dependently
improved survival rates as compared with scrambled peptidetreated controls (Fig. 6 C). Importantly, P5779 was effective
even when administered 24 h after onset of the peritonitis,
10

consistent with the known delayed pathogenic role of HMGB1
in sepsis sequelae. Collectively, these results indicate that P5779
disrupts binding of disulfide HMGB1 to MD-2, thereby attenuating HMGB1-mediated organ failure and mortality in vivo.
These results reveal a novel mechanism of selective innate
immune cell recognition of HMGB1 by MD-2 that discriminates the HMGB1 isoforms. By screening HMGB1 peptide
libraries, we identified a novel tetramer peptide (FSSE, P5779)
that specifically prevents the MD-2–HMGB1 interaction
without impairing the MD-2/LPS/TLR4 signaling in innate
immune cells. This peptide conferred protection not only in
animal models of sterile injury-elicited inflammatory diseases
but also after a lethal infection challenge, opening the possibility of developing novel therapeutic strategies to attenuate
MD-2–HMGB1 interplay and TLR4 signaling | Yang et al.
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Figure 6. Treatment with the HMGB1 inhibitor P5779 ameliorates APAP-mediated toxicity, I/R injury, and sepsis mortality in vivo. (A, top left)
C57BL/6 mice received an APAP injection (i.p.; see Materials and methods) and were administered with P5779 (at doses indicated) or control peptide (ctrl;
500 µg/mouse, i.p.). Mice were euthanized at 24 h after APAP, and serum enzyme (ASL and ALT) and cytokine (TNF) levels were measured by ELISAs. n = 6–10
mice per group. (bottom left) In survival experiments, mice received an APAP injection (i.p.) and were administered with P5779 or control peptide (i.p.; see
Materials and methods). Survival was monitored for 2 wk (percent survival). n = 30 mice/group. (right) Representative H&E images of liver tissue sections are
shown for normal (untreated) or APAP-injected mice receiving P5779 or control peptides. Clinical scores were assessed and are shown on the right. Liver
necrosis is demonstrated by an arrow. n = 6–10 mice/group. *, P < 0.05 versus control peptide group. (B, left) P5779 or control peptide was administered
(500 µg/mouse, i.p.) at the time of I/R surgery, and mice were euthanized 6 h later to measure serum levels of ALT and AST and to evaluate histological liver
injury. *, P < 0.05 versus I/R group. n = 5–7 mice/group. (right) Representative H&E liver tissue sections are shown (neutrophil infiltration: arrow). n = 3–5
mice per group. (A and B) Data are presented as means ± SEM. Bars, 100 µm. (C) Mice received CLP surgery, and P5779 or control peptide was administered
i.p. at the doses indicated. Animal survival was monitored for 2 wk (percent survival). *, P < 0.05 versus control peptide group. n = 20 mice/group.

DAMP-mediated injurious inflammatory responses without
inhibiting PAMP-elicited innate immunity.
MD-2 carries a -cup fold structure composed of two
antiparallel -sheets that form a large hydrophobic pocket for
binding to LPS (Park et al., 2009). The estimated affinity of
MD-2 binding to HMGB1 (12 nM) is comparable with MD2 binding to LPS (65 nM;Visintin et al., 2006). Further structural analysis is required to reveal the disulfide HMGB1-binding
site on MD-2.
HMGB1-neutralizing antibodies are protective against sterile injury (Tsung et al., 2005), and agents capable of inhibiting
HMGB1 release or its extracellular activities (Wang et al.,
1999; Yang et al., 2004) also confer protection against sepsis.
During early stages of sepsis, PAMP-mediated inflammatory
responses are essential to host defense. At later stages, the release of DAMPs amplifies the cytokine storm and organ dysfunction (Wang et al., 2014). This notion is supported by
JEM Vol. 212, No. 1

recent observations that HMGB1 levels are persistently elevated during later stages of sepsis, despite termination of the
initial infection, and contribute to long-term pathological
consequences of sepsis (Valdés-Ferrer et al., 2013). Microbialinduced sepsis can be clinically indistinguishable from the
sterile injury-elicited systemic inflammatory response syndrome (SIRS; Sursal et al., 2013). Based on the findings that
TLR4–MD-2 acts as a mutually exclusive signaling receptor
complex for disulfide HMGB1, it is possible to develop strategies that selectively attenuate DAMP-mediated inflammatory responses while preserving PAMP-mediated signaling.
Substantial evidence supports the necessity to preserve early
PAMP-mediated innate immune responses to counteract
microbial infections. For instance, defective TLR4 signaling in
C3H/HeJ mice is associated with aggravated disease severity and
increased mortality in animal models of infection (Khanolkar
et al., 2009). LPS enhances macrophage phagocytic activity
11

through TLR4, and selective deletion of TLR4 on myeloid cells
impairs bacterial clearance in the CLP model (Deng et al.,
2013). These findings emphasize the importance of generating
therapeutic approaches to selectively target damage-mediated
inflammation while preserving physiological protective immune responses.The discovery of P5779 as an MD-2–targeting
selective inhibitor for the DAMP- but not the PAMP-elicited
inflammatory responses provides such a novel therapeutic tool.
MATERIALS AND METHODS
Reagents. Human TLR4–MD-2 complex, human MD-2, TLR2, and soluble RAGE were obtained from R&D Systems. LPS (Escherichia coli; 0111:B4),
APAP, Triton X-114, PGN from Bacillus subtilis, blasticidin S, NaSH, mouse
IgG, and human macrophage-CSF (M-CSF) were purchased from SigmaAldrich. Protein A/G agarose and isopropyl-d-thiogalactopyranoside (IPTG)
were from Thermo Fisher Scientific. NHS-activated Sepharose 4 fast flow
beads were obtained from GE Healthcare. Thioglycollate medium was purchased from BD. Ultrapure LPS, Poly I:C, and type B CpG oligonucleotide
were obtained from InvivoGen. Human S100 A12 was from Circulex Co.
Anti–human and –mouse MD-2 antibodies were obtained from Imgenex.
Anti-CBP tag antibody was from GenScript.Anti-p50 antibody (E381) and antip65 antibody were obtained from Epitomics and Santa Cruz Biotechnology,
Inc., respectively. Serum ALT and AST levels were determined by color endpoint assay kits from BIOO Scientific.
Preparations of HMGB1 proteins, antibodies, and peptides. Recombinant HMGB1 was expressed in E. coli and purified to homogeneity as described previously (Wang et al., 1999; Li et al., 2004). This cytokine-stimulating
HMGB1 contains a disulfide bond between cysteines 23 and 45 and reduced
thiol on cysteine 106, characterized by liquid chromatography tandem mass
spectrometric analysis (LC-MS/MS;Yang et al., 2012). HMGB1 with redox
modifications was created chemically by a synthetic formation of mercury
thiolate on cysteine at position 106 (Hg-HMGB1), by S-sulfhydration (H2S)
to convert cysteine thiol (-SH) group to -SSH or by mutation of cysteine
106 to alanine (C106A HMGB1) as described previously (Yang et al., 2010,
2012). HMGB1 with cysteine modified by H2S was generated by incubating
HMGB1 with 5 mM NaSH for 3 h at room temperature. Oxidized or DTTreduced HMGB1 was prepared as previously described (Yang et al., 2012).
The LPS content in HMGB1 was measured by the Chromogenic Limulus
Amebocyte Lysate Assay (Lonza). HMGB1 was extracted with Triton X-114
to remove any contaminating LPS as described previously (Li et al., 2004).
The purity and integrity of all recombinant proteins were verified by Coomassie blue staining after SDS-PAGE, with a purity predominantly >85%.
The LPS content in all HMGB1 protein preparations is undetectable or
<10 pg/mg protein as measured by Limulus assay. Anti-HMGB1 mAb (2g7)
was generated as reported previously (Qin et al., 2006). Trimer or tetramer
peptides (FSSE, FSSEY, FEEE, FEED, SSE, and SFSE) and CBP (MKRRWKKNFIAVSAANRFKKISSSGAL) were all custom-made from GeneMed Inc.
The peptides were purified to 90% purity as determined by HPLC. Endotoxin was not detectable in the synthetic peptide preparations as measured by
Limulus assay.The peptides were first dissolved in DMSO and further diluted
in PBS as instructed by the manufacturer and prepared freshly before use.
Pre-casted mini-protean Tris-Tricine gels were from Bio-Rad Laboratories.
Cell isolation and culture. Thioglycollate-elicited peritoneal macrophages
were obtained from mice (C57BL/6 or gene knockout, male, 10–12 wk old)
injected with 2 ml of sterile 4% thioglycollate broth i.p. as previously described (Yang et al., 2010). Murine macrophage-like RAW 264.7 and human
leukemia monocytes THP-1 were obtained from ATCC. Human primary
monocytes were purified by density gradient centrifugation through Ficoll
from blood donated by normal individuals as reported previously (Yang et al.,
2010). Human primary macrophages in 96-well plates were stimulated with
HMGB1 at 1 µg/ml, TLR4 agonist LPS at 4 ng/ml, TLR3 agonist Poly I:C
at 50 µg/ml, TLR2 agonist PGN at 5 µg/ml, RAGE agonist S100A12 at
12

50 µg/ml, and TLR9 agonist CpG DNA at 1 µM, plus increasing amounts of
P5779 (or scrambled control peptide) as indicated for 16 h. TNF release was
measured by ELISA.
Immunoprecipitation assay. Recombinant rat HMGB1 with a CBP tag
or 10 µg CBP peptide alone was incubated overnight with 50 µl human
MD-2 supernatant (precleared with calmodulin beads) at 4°C with gentle
shaking. Human MD-2 supernatant was obtained from sf9 insect cells transfected with human MD-2 (Teghanemt et al., 2008). Both HMGB1 and MD-2
supernatant contained nondetectable amounts of LPS as measured by Limulus amebocyte lysate assay.The mixture of CBP-HMGB1 or CBP and MD-2
was then incubated with calmodulin beads (30 µl drained beads) for 1 h at
4°C. After extensive washing with PBS containing 0.1% Triton X-100, proteins bound to the beads were analyzed by Western blot probed with anti–
human MD-2 or anti-CBP antibodies.
Cytokine and NF-B measurements. Levels of TNF and IL-6 released
in the cell culture or from mice serum were measured by ELISA kits (R&D
Systems). Serum HMGB1 levels were measured by ELISA kit (IBL International). Cytokine expression profile from thioglycollate-elicited peritoneal
macrophages of mice or primary human macrophages was determined by
mouse or human cytokine array C1 (Raybiotech) according to the manufacturer’s instructions. 22 cytokines or chemokines were determined simultaneously. NF-B activation was analyzed by detecting p50 and p65 expression in
the nuclear fraction by Western blot. -Actin expression was also measured as
control for equal loading of samples.Western blots were scanned with a silver
image scanner (Silver-scanner II; Lacie Limited), and the relative band intensity was quantified using ImageJ software (v1.59; National Institutes of
Health) and expressed as a ratio to the amount of -actin.
SPR analysis. The Biacore T200 instrument was used for real-time binding
interaction experiments. For HMGB1–MD-2 binding analyses, human MD-2
was immobilized onto a CM5 series chip (GE Healthcare). One flow cell was
used as a reference and thus immediately blocked upon activation by 1 M ethanolamine, pH 8.5. The sample flow cell was injected with disulfide HMGB1
(or isoforms; in 10 mM acetate buffer, pH 5.2) at a flow rate of 10 µl/min for
7 min at 25°C. Increasing concentrations of disulfide HMGB1 or isoforms of
HMGB1 (C106A, sulfonyl, fully reduced, Hg, or H2S-modified HMGB1 at
1 µM) were flowed over immobilized MD-2. In reverse fashion, HMGB1 was
coated on the chip and various amounts of MD-2 were added as analyte. Findings were confirmed by using two additional human MD-2 proteins from D.
T. Golenbock and T.R. Billiar. For TLR4-HMGB1 binding experiments,
human TLR4 was coated on the chip, and 100 nM disulfide HMGB1 was
added as analyte. For peptide screening experiments, human MD-2 was coated
on the sensor chip, trimer, or 100 nM tetramer peptides (FSSE, FSSEY, FEEE,
FEED, SSE, and SFSE) were added as analytes. The dissociation time was set
for 2 min, followed by a 1-min regeneration using a 10 mM NaOH solution.
The Kd was evaluated using the Biacore evaluation software. For experiments
using HMGB1 antibody to block MD-2–HMGB1 interaction, human MD-2
was coated on the chip, HMGB1 was added as analyte (100 nM) plus increasing
amounts of HMGB1 mAb or control IgG, and response units were recorded.
Molecular docking of MD-2 with peptides. The crystal structure of the
MD-2–TLR4 was obtained from the Protein Data Bank (PDB code: 3VQ2),
and molecular docking was performed by using the MOE software as previously described (Zan et al., 2012). A molecular visualization system, the
PyMOL 0.99, was used to construct the three-dimensional figures.
Knockdown MD-2 in RAW 264.7 and THP-1 cells using siRNA. For
MD-2 knockdown in RAW 264.7 cells, cells were transfected with mouse
MD-2 or 50 nM control siRNA (on-target plus smart pool; GE Healthcare)
using DharmaFect1 transfection reagent. To knock down MD-2 in THP-1
cells, transfection with MD-2–specific siRNA was performed by using an
Amaxa Nucleofector kit (Lonza). The efficiency of knockdown was confirmed
by Western blot probed with anti–MD-2 antibody at 48 h after transfection.
MD-2–HMGB1 interplay and TLR4 signaling | Yang et al.
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At 48 h after transfection, cells were stimulated with 1 µg/ml HMGB1 for 16 h.
Cell lysate and supernatant were collected and analyzed by Western blot or
ELISA. NF-B measurements on RAW 264.7, THP-1, or primary mouse
macrophages from MD-2 KO mice were performed using NE-PER Protein
Extraction kit (Thermo Fisher Scientific).

t test and one-way ANOVA followed by the least significant difference test.
Differences between groups in animal survival experiments were determined
using two-tailed Fisher’s exact test. Cytokine array experiments were analy
zed using the software UN-Scan-it from Silk Scientific Inc. P-values <0.05
were considered statistically significant.

Animals. Male C57BL/6 mice were obtained from the Jackson Laboratory.
MD-2 KO (on C57BL/6 background) mice were purchased from the
RIKEN Bio-Resource Center. All animals were maintained at The Feinstein
Institute for Medical Research or University of Pittsburgh under standard
temperature and light cycles, and all animal procedures were approved by the
institutional animal care and use committee.
For genotyping of MD-2 KO mice from tail snips, PCR primers were
designed by the RIKEN Bio-Resource Center and were obtained from
Invitrogen. The same primers were used to identify WT (PCR product =
2,000 bp) and MD-2 KO (PCR product = 800 bp) in genotyping.
For murine hepatic warm I/R, a 70% warm liver I/R model was performed as previously described (Tsung et al., 2005). Mice received i.p. injections of P5779 (500 µg/mouse) or vehicle at the time of surgery and were
euthanized at 6 h afterward. Whole blood was collected by cardiac puncture,
and liver was harvested and fixed in 10% formalin for analysis.
For CLP, C57BL/6 mice (male, 8–12 wk of age) were subjected to CLP
procedure as described previously (Yang et al., 2004). P5779 or scrambled
control peptide was administered i.p. at 50 or 500 µg/mouse, and treatment
was given once a day for 4 d starting at 24 h after CLP surgery. Survival was
monitored for 2 wk.
For the APAP hepatic toxicity model, three sets of experiments were conducted. In all experiments, mice were routinely fasted overnight and received
i.p. injection of APAP (350 mg/kg for survival experiments and 400 mg/kg
for serum measurements when mice were euthanized at 24 h after APAP) as
previously described (Antoine et al., 2012; Yang et al., 2012). The first set of
experiments was performed using male MD-2 KO or C57BL/6 mice (8–12
wk old). Mice had APAP injection and were euthanized 24 h later (for serum
measurements) or monitored for 2 wk (for survival experiments).The second
set of experiments was performed using anti-HMGB1 antibody in the APAP
model in WT male (C57BL/6) mice. In survival experiments, mice had APAP
injection and received anti-HMGB1 antibodies (5 µg/mouse, i.p. once daily
for 4 d followed by two additional doses once every other day beginning at
2 h after APAP). Irrelevant nonimmune IgG was used as a control. For serum
measurements, mice were subjected to APAP injection and received injection
of anti-HMGB1 mAb (5 µg/mouse, injected i.p. at 2 and 7 h after APAP) and
euthanized at 24 h after APAP.The third set of experiments was used to assess
the efficacy of P5779 in the APAP model in WT mice. Male C57BL/6 mice
received APAP injection plus P5779 (at 50 or 500 µg/mouse) or scrambled
control peptide (500 µg/mouse, i.p. injected at 2 and 7 h after APAP) and euthanized at 24 h after APAP. In survival experiments, mice had injection of
APAP and received treatment of P5779 or control peptide (500 µg/mouse,
i.p. once a day for 5 d starting at 2 h after APAP), and survival was monitored
for 2 wk. Hepatotoxicity was determined by serum levels of GLDH, ALT, and
AST as described previously (Antoine et al., 2013).
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Histological evaluation. Harvested livers were fixed in 10% formalin and
embedded in paraffin. 5-µm sections were stained with hematoxylin and
eosin (H&E). H&E staining of livers was performed by AML Laboratory.The
liver histology was evaluated in a blinded fashion, and clinical scores were
calculated based on the amount of necrosis and inflammation (cell swelling,
loss of tissue structure, and congestion) using a previously reported method
with modifications (Desmet, 2003). Score 0 = no evidence of necrosis or
inflammation as assessed from three to four representative sections from each
animal; 1 = mild necrosis or inflammation (<25% of the total area examined);
2 = notable necrosis and inflammation (25–50% of the total area); 3 = severe
necrosis and inflammation (>50% area).
Statistical analysis. Data are presented as means ± SEM unless otherwise
stated. Differences between treatment groups were determined by Student’s
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